News & Updates
Showing Cardiology articles
Showing
Show Multimedia Only

Tirzepatide trims risk of major adverse cardiovascular events
26 Nov 2025
byStephen Padilla
Treatment with tirzepatide 15 mg/week results in a 33-percent reduction in the risk of major adverse cardiovascular events (MACE), results of a meta-analysis have shown. Moreover, its efficacy is consistent across individuals with or without obesity.
26 Nov 2025

Tirzepatide may reduce major kidney events in T2D patients with CVD, CKD
25 Nov 2025
byStephen Padilla
The use of tirzepatide appears to reduce decline in kidney function, prevent albuminuria progression, and lower the risk of the composite kidney outcome compared with dulaglutide in patients with type 2 diabetes (T2D), atherosclerotic cardiovascular disease (ASCVD), and very high-risk chronic kidney disease (CKD), reports a study presented at Kidney Week 2025.
25 Nov 2025







